The KMT2A-AFF1 rearrangement mostly participates in the leukemic progression as a second hit, and B-ALL patients with this fusion protein possess a significantly promoted MYC gene expression in comparison to patients with AML [475, 476]. Here, MYC is linked to acute lymphoblastic leukemia.